The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, MyelomaMay 14, 2020
The European Medicines Agency (EMA) recommends extension of indications for daratumumabAccess, MyelomaOctober 21, 2019
European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myelomaAccess, MyelomaAugust 28, 2019
Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)Access, MyelomaJuly 19, 2019
Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, MyelomaMay 23, 2019
Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on accessAccess, MPEMay 6, 2019
